Transplantation Infection Clinical Trial
Official title:
Prevention of Healthcare Associated Infections in Bone Marrow Transplant Patients
NCT number | NCT02463214 |
Other study ID # | H15-00662 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | September 2015 |
Est. completion date | March 2018 |
Verified date | April 2019 |
Source | University of British Columbia |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study involves sampling bone marrow transplant patients, hospital workers and the patient room for microbes using swabs and other techniques. We send these samples to the laboratory, where they will use state-of-the art technology to identify and relate the microbes to each other. This study also involves putting copper, nickel, or titanium into some hospital rooms, and seeing whether these metals influences the growth of microbes. Some equipment in the hospital room, such as faucets and soap dispensers will be replaced by sensor-based (e.g. touchless) controls.
Status | Completed |
Enrollment | 45 |
Est. completion date | March 2018 |
Est. primary completion date | March 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 19 Years to 75 Years |
Eligibility |
Inclusion Criteria (Patients): - undergoing allogenic bone marrow transplant for acute myeloid leukemia - will be admitted to the leukemia and bone marrow transplant service at Vancouver General Hospital - admission to the ward anticipated to be approximately 28 days Exclusion Criteria (Patients): - allergies to copper, nickel or titanium - patients admitted for stays anticipated to be less than 28 days Inclusion Criteria (Health care worker): - undergoing allogenic bone marrow transplant for acute myeloid leukemia - caring for patient enrolled in the study as a primary nurse Exclusion Criteria (Health care worker): - allergies to copper, nickel or titanium |
Country | Name | City | State |
---|---|---|---|
Canada | Vancouver General Hospital | Vancouver | British Columbia |
Lead Sponsor | Collaborator |
---|---|
University of British Columbia | Vancouver Coastal Health Research Institute |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in bioburden on surfaces | Looking to see the effectiveness of copper and titanium on the microbiota in the environment of the recovery room. | up to 28 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05047406 -
Bacillus Clausii in Liver Transplantation
|
Phase 2 | |
Recruiting |
NCT05198570 -
Pharmacokinetics of Intravenous Acyclovir in Oncologic Paediatric Patients
|
||
Completed |
NCT01808456 -
Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.
|
Phase 4 | |
Suspended |
NCT01301118 -
Graft Take and Microbiology in Burns
|
N/A | |
Completed |
NCT00610961 -
Induction Related BK Viremia in Renal Transplant Patients
|
Phase 4 | |
Recruiting |
NCT05215327 -
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
|
Phase 2 | |
Recruiting |
NCT05193058 -
Description of Lung Transplant Patients With Microbiologically Documented Stenotrophomonas Maltophilia Pneumonia and Impact of Treatment on Outcome
|
||
Unknown status |
NCT01983761 -
Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02811835 -
TransplantLines Food and Nutrition Biobank and Cohort Study (TxL-FN)
|
N/A | |
Completed |
NCT01471444 -
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
|
Phase 3 | |
Enrolling by invitation |
NCT01349738 -
Asymptomatic Bacteriuria & Risk of Urinary Tract Infection in Renal Transplants
|
N/A | |
Terminated |
NCT00473824 -
Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation
|
Phase 2 | |
Completed |
NCT01276457 -
Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients
|
Phase 3 | |
Completed |
NCT00177801 -
Organ Transplant Infection Prevention and Detection Project
|
Phase 4 | |
Completed |
NCT02328963 -
Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A
|
Phase 4 | |
Recruiting |
NCT04320303 -
CMV Infection and Immune Intervention After Transplantation
|
N/A | |
Active, not recruiting |
NCT01295645 -
Cidofovir Versus Best Supportive Care for Hemorrhagic Cystitis
|
Phase 2 | |
Completed |
NCT02329808 -
Clinical Validation of a Dried Blood Spot Method for Analysis of Immunosuppressives and Antifungals in Pediatrics
|
||
Completed |
NCT01471067 -
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies
|
Phase 1 | |
Recruiting |
NCT04579471 -
Prevalence and Outcome of SARS-CoV-2 Infection & COVID-19 in Transplant Recipients: The COVITRA Study
|